Jefferson scientists find way to see breast cancer activity from outside the body

December 09, 2004

Using precise, radioactively labeled genetic probes, researchers at Jefferson Medical College have seen cancer gene activity from outside the body in laboratory mice. The probes, which work by attaching to genetic codes copied from an active cancer gene, may someday aid physicians and scientists in cancer detection and in determining the appropriate treatment for a cancer.

"Patients might be able to avoid a great deal of worry and unneeded surgery if cancer gene activity could be detected from outside the body," says Eric Wickstrom, Ph.D., professor of biochemistry and molecular pharmacology and microbiology and immunology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and at Jefferson's Kimmel Cancer Center.

The scientists would like to detect cancerous breast tumors as early as possible, particularly before they begin to spread to other areas of the body. "We want to detect them before mammograms can find them," Dr. Wickstrom says. "We want to see whether a cancer gene is active, which will tell clinicians the best way to treat it, according to the cancer gene activity of the tumor. If we can see the hotspot of cancer gene activity before the tumor has formed, we can start to treat earlier." The researchers report their results in December in the Journal of Nuclear Medicine.

The gene, called cyclin D1, is turned on in the majority of breast cancers, he explains. The genetic probe, which is a DNA derivative, carries an attached radioactive label, and binds to cyclin D1 messenger RNA (mRNA). The latter is involved in translating DNA instructions and making proteins.

Dr. Wickstrom, Mathew Thakur, Ph.D., professor of radiology at Jefferson Medical College and their co-workers contend that the strategy - using genetic probes to visualize sites of cancer gene activity - can work for detecting the activity of other cancer genes in various types of tumors.

"The radioactive probes can help us identify the cancer cells at an early stage," says Dr. Thakur. "In this technology, we've shown the proof of principle. Several other cancers show characteristic activated genes that we might also be able to use for early diagnosis, such as pancreatic cancer, prostate cancer and colon cancer."

In 2004, approximately 40,000 women in this country will die from breast cancer. According to Dr. Wickstrom, clinical examination and mammography miss almost half of the breast cancers in women under 40, approximately one quarter of cancers in women ages 40 to 49 and one-fifth of cancers in women over age 50.

He notes that when suspect lumps are discovered, biopsies are necessary to tell if cancer exists or not. But when such lumps are removed after suspicious mammograms, two-thirds are found to be benign.

Dr. Wickstrom foresees this particular test for cyclin D1 - which he has used to detect estrogen receptor-positive breast cancers in mice - eventually being used in medical imaging centers. In addition to a mammogram, a woman could be tested with a genetic probe - another way, he says, to screen suspicious lumps. It could also be used to detect precancerous zones, as in ductal carcinoma in situ, and the spread and recurrence of cancer.

The researchers hope to conduct a clinical trial of their probes in suspected cases of breast cancer, and eventually, in other cancers as well. They are publishing their results testing for another cancer gene called MYC next month, and are studying other known cancer genes, such as K-RAS in pancreatic cancer.
-end-


Thomas Jefferson University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.